Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits

Acta Pharmacol Sin. 2007 Jan;28(1):58-65. doi: 10.1111/j.1745-7254.2007.00455.x.

Abstract

Aim: To investigate the thrombolytic efficacy, ideal dosage and administration of native recombinant staphylokinase (r-SAK).

Methods: Forty New Zealand rabbits were randomly assigned into the control, r-SAK low-dose, medial-dose, high dose, single bolus, allied therapy, recombinant streptokinase (r-SK) and urokinase (UK) groups. The right femoral artery thrombosis models were made by balloon injury, and 120 min after the injury, the thrombolytic agents were infused through the rabbits' parallel-ear vein.

Results: (1) 2 h after balloon injury, the pulse pressures of the right femoral arteries reduced to 0 or less than 10% of that of left femoral arteries in all groups; (2) after thrombolytic therapy, the pulse pressures in some of the femoral arteries markedly enhanced to more than 50% of that of left femoral arteries; (3) the reopening rates in the r-SAK medial and high dose groups were significantly higher than that of the control. The reopening rate of the same dose native r-SAK was significant higher than that of UK and r-SK; (4) the patency score of the right femoral arteries tended to be better in the r-SAK medial and high-dose groups than that of the low-dose group, and the time to reopening in the allied therapy group tended to be shorter.

Conclusion: (1) r-SAK has a definite thrombolytic effect on the femoral artery thrombus of rabbits; (2) single bolus is an effective manner of r-SAK therapy, and r-SAK allied therapy with heparin may shorten the time to recanalization; (3) the efficacy of the same dose native r-SAK was superior to that of r-SK and UK.

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Femoral Artery / drug effects*
  • Femoral Artery / pathology
  • Femoral Artery / physiopathology
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use*
  • Heparin / therapeutic use
  • Male
  • Metalloendopeptidases / administration & dosage
  • Metalloendopeptidases / genetics
  • Metalloendopeptidases / therapeutic use*
  • Rabbits
  • Random Allocation
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Thrombosis / drug therapy*
  • Thrombosis / pathology
  • Thrombosis / physiopathology
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Recombinant Proteins
  • Heparin
  • Metalloendopeptidases
  • auR protein, Staphylococcus aureus